AI-POWR

AI-POWR

Encerrada

Nominativa · Brasil

TecnologiaSoftware e TI

Andamento no INPI

Depósito29/12/20
Publicação27/07/21
Arquivado
Deferimento
Concessão
Vigente

Pedido arquivado pelo INPI. O processo foi encerrado sem chegar a registro.

Verificar se este nome está livre

Última movimentação publicada pelo INPI: 09/08/2022 (RPI 2692). Atualizamos a cada nova RPI, publicada semanalmente.

Esta marca está encerrada — vale investigar antes de avançar

A marca "AI-POWR" não aparece como ativa no momento. Isso pode abrir espaço de mercado, mas o histórico completo e eventuais conflitos merecem revisão antes de avançar.

Panorama da marca

Situação INPI: Designação definitivamente arquivada
Idade do processo: 5 anos e 8 meses
Eventos no processo: 3
Última atualização: 09 de agosto de 2022

Dados do processo

Titular: Hepion Pharmaceuticals, Inc.
Número do processo: 501597990
Número de registro: 501597990
Natureza: Madri Produto/Serviço
Data do depósito: 29 de dezembro de 2020
Válido até: 29 de dezembro de 2030

Produtos e serviços cobertos

Classe 9 — Tecnologia

Computer software for using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological fieldcomputer software for integrating artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation with disease studies and investigations, pharmaceutical and drug research and development, biomedical, biological, and biotechnological research and development, and pharmacology, clinical pharmacology, system pharmacology, and system biologycomputer software for clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulationcomputer software for patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulationcomputer software for drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, accessing, processing, and analyzing public and proprietary omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data via a global computer network using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulationcomputer software for disease studies and investigations, understanding of diseases, pharmaceutical and drug research and development, biomedical, biological, and biotechnological research and development, and pharmacology, clinical pharmacology, system pharmacology, system biology research and development using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation

Classe 42 — Software e TI

Design, development, programming, testing, maintenance, customization, and operation of computer software in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulationconsulting, consultancy, and consulting services related to clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and related to the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations)platform as a service (PaaS) featuring computer platforms and software for using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological fieldsoftware as a service (SaaS) featuring computer platforms for using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological fieldresearch and development in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulationperforming clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and services in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation for others (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations)

Linha do tempo do processo

3 eventos

Movimentações mais recentes da marca “AI-POWR” publicadas na Revista da Propriedade Industrial (RPI). O detalhe de cada despacho fica na consulta completa.

Ação / prazo09 de ago. de 2022RPI 2692
Arquivamento definitivo de designação por falta de cumprimento de exigência de mérito
Detalhes na consulta completa
Ação / prazo03 de mai. de 2022RPI 2678
Exigência de mérito em designação
Detalhes na consulta completa
Ação / prazo27 de jul. de 2021RPI 2638
Publicação de pedido de registro para oposição (exame formal de designação concluído)
Detalhes na consulta completa

O que fazer se a sua marca se aproxima de "AI-POWR"?

Conflitos de marcas no Brasil são resolvidos com base na anterioridade do depósito, nas classes de Nice e no segmento de atuação. O processo tem várias fases e pode ficar complexo quando o nome é parecido ou o mercado se cruza. Uma leitura cuidadosa ajuda a decidir se vale seguir, ajustar ou recuar.

A TrademarkIQ cruza histórico, decisões e padrões de aprovação por classe e setor em uma base com +6 milhões de processos brasileiros. Isso ajuda a enxergar o risco com mais contexto e a encontrar o melhor caminho comercial e jurídico para a sua marca.

Receber alertas desta marca Ver todas as marcas similares

Marcas semelhantes

Outros processos no INPI com nome próximo de "AI-POWR".

UPOWR

Registrada · Classe 9, 35, 37

POWRAY

Em análise · Classe 12

MAGPOWR

Registrada · Classe 9

POWRESI

Registrada · Classe 5

POWRGRIP

Registrada · Classe 7

VYMPOWRI

Em análise · Classe 5

POWR-TROL

Encerrada · Classe 7

TRANSPOWR

Registrada · Classe 9

Outras marcas do titular

Processos de marca no INPI em nome de Hepion Pharmaceuticals, Inc..

HEPION PHARMACEUTICALS

Registro de marca em vigor (Madri) · Classe 5

Escritórios especializados

Notória Marcas e Patentes

88% aprovação

Mark-se Marcas

71% aprovação

Marfim Marcas e Patentes

67% aprovação

Ver todos os escritórios →

Quer registrar a sua marca?

1Diga o nome e o ramo. A análise de anterioridade sai da base oficial do INPI, a mesma que você acabou de consultar.
2Um escritório verificado assume o caso, define as classes e a especificação, e protocola no INPI.
3Você recebe o número do processo e acompanha cada despacho até a decisão final.

Falar com um escritório verificado

Sem custo para pedir a análise. O preço depende do escritório e do caso.

Vigilância de marca

Seja avisado antes que vire problema

Monitoramento contínuo: receba um alerta a cada novo depósito que possa colidir com AI-POWR ou com a sua marca — a tempo de se opor dentro do prazo.

Monitorar marca

Dados atualizados a partir de uma base com +6 milhões de marcas brasileiras analisadas. Esta página é informativa e não substitui parecer jurídico, mas ajuda a orientar a decisão com mais contexto comercial e técnico.